Showing 37 to 48 of 128 results
Global Obesity Crisis: 60% of Adults, One-Third of Children Projected to be Overweight or Obese by 2050
A new Lancet study projects that nearly 60 percent of adults and one-third of children globally will be overweight or obese by 2050 without governmental intervention, highlighting a critical public health challenge with significant implications for healthcare systems worldwide.
Global Obesity Crisis: 60% of Adults, One-Third of Children Projected to be Overweight or Obese by 2050
A new Lancet study projects that nearly 60 percent of adults and one-third of children globally will be overweight or obese by 2050 without governmental intervention, highlighting a critical public health challenge with significant implications for healthcare systems worldwide.
Progress
40% Bias Score
Global Obesity Crisis to Affect 4.5 Billion by 2050
Two studies published in The Lancet predict that by 2050, 60% of adults and 31% of children globally will be overweight or obese, totaling 3.8 billion adults and 746 million young people, a sharp increase from 1990, posing a major threat to global health.
Global Obesity Crisis to Affect 4.5 Billion by 2050
Two studies published in The Lancet predict that by 2050, 60% of adults and 31% of children globally will be overweight or obese, totaling 3.8 billion adults and 746 million young people, a sharp increase from 1990, posing a major threat to global health.
Progress
40% Bias Score
Global Obesity Epidemic Predicted by 2050 Unless Governments Act
A Lancet study predicts a global obesity epidemic by 2050, affecting 60% of adults and one-third of children and adolescents unless governments implement significant preventative measures; the study is based on data from 204 countries and territories, showing a substantial increase in obesity rates ...
Global Obesity Epidemic Predicted by 2050 Unless Governments Act
A Lancet study predicts a global obesity epidemic by 2050, affecting 60% of adults and one-third of children and adolescents unless governments implement significant preventative measures; the study is based on data from 204 countries and territories, showing a substantial increase in obesity rates ...
Progress
48% Bias Score
GLP-1 Agonist Shows Significant Promise in Treating Obstructive Sleep Apnea
A year-long study published in The New England Journal of Medicine showed that tirzepatide, a GLP-1 agonist, reduced the apnea-hypopnea index by almost 59% in 469 obese individuals with moderate-to-severe obstructive sleep apnea, alongside an average 20% weight loss; this may reduce reliance on CPAP...
GLP-1 Agonist Shows Significant Promise in Treating Obstructive Sleep Apnea
A year-long study published in The New England Journal of Medicine showed that tirzepatide, a GLP-1 agonist, reduced the apnea-hypopnea index by almost 59% in 469 obese individuals with moderate-to-severe obstructive sleep apnea, alongside an average 20% weight loss; this may reduce reliance on CPAP...
Progress
48% Bias Score
Mediterranean Diet Linked to 6% Lower Obesity-Related Cancer Risk
A new study of over 450,000 people in Europe revealed that closely following the Mediterranean diet reduces obesity-related cancer risk by 6%, regardless of BMI, suggesting other health benefits contribute to cancer prevention.
Mediterranean Diet Linked to 6% Lower Obesity-Related Cancer Risk
A new study of over 450,000 people in Europe revealed that closely following the Mediterranean diet reduces obesity-related cancer risk by 6%, regardless of BMI, suggesting other health benefits contribute to cancer prevention.
Progress
52% Bias Score
European Life Expectancy Slowdown Linked to Lifestyle Factors
A new study in The Lancet Public Health reveals a slowdown in Europe's life expectancy increase since 2011, attributed to rising obesity, inactivity, and poor diet, with the COVID-19 pandemic worsening the situation; this deceleration varies across countries, with the UK experiencing significant cha...
European Life Expectancy Slowdown Linked to Lifestyle Factors
A new study in The Lancet Public Health reveals a slowdown in Europe's life expectancy increase since 2011, attributed to rising obesity, inactivity, and poor diet, with the COVID-19 pandemic worsening the situation; this deceleration varies across countries, with the UK experiencing significant cha...
Progress
28% Bias Score
Global Obesity Crisis: 2050 Projections Reveal Unprecedented Threat
A Lancet report warns that over half of adults and a third of children worldwide will be overweight or obese by 2050, driven by decades of insufficient action, resulting in a massive increase in related diseases and overwhelming healthcare systems.
Global Obesity Crisis: 2050 Projections Reveal Unprecedented Threat
A Lancet report warns that over half of adults and a third of children worldwide will be overweight or obese by 2050, driven by decades of insufficient action, resulting in a massive increase in related diseases and overwhelming healthcare systems.
Progress
28% Bias Score
Global Obesity Crisis: Projections for 2050
By 2050, over half of adults and a third of children and adolescents globally will be overweight or obese, posing an unprecedented threat to health and healthcare systems, exceeding 2.11 billion adults and 493 million children/youth currently affected, according to a Lancet study.
Global Obesity Crisis: Projections for 2050
By 2050, over half of adults and a third of children and adolescents globally will be overweight or obese, posing an unprecedented threat to health and healthcare systems, exceeding 2.11 billion adults and 493 million children/youth currently affected, according to a Lancet study.
Progress
24% Bias Score
Weight-Loss Jabs Show Promise in Reversing Liver Damage
Weight-loss injections, such as Ozempic and Wegovy, containing semaglutide, are showing promise in reversing severe liver damage caused by non-alcoholic fatty liver disease (NAFLD), according to a King's College London study; this offers hope for the millions of people who have this condition, cases...
Weight-Loss Jabs Show Promise in Reversing Liver Damage
Weight-loss injections, such as Ozempic and Wegovy, containing semaglutide, are showing promise in reversing severe liver damage caused by non-alcoholic fatty liver disease (NAFLD), according to a King's College London study; this offers hope for the millions of people who have this condition, cases...
Progress
56% Bias Score
Mediterranean Diet Linked to 6% Lower Obesity-Related Cancer Risk
A new study of over 450,000 people found that closely following the Mediterranean diet reduced the risk of obesity-related cancers by approximately 6%, regardless of BMI, potentially due to factors beyond weight loss such as reduced inflammation, suggesting its significant role in cancer prevention ...
Mediterranean Diet Linked to 6% Lower Obesity-Related Cancer Risk
A new study of over 450,000 people found that closely following the Mediterranean diet reduced the risk of obesity-related cancers by approximately 6%, regardless of BMI, potentially due to factors beyond weight loss such as reduced inflammation, suggesting its significant role in cancer prevention ...
Progress
44% Bias Score
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market
Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.
Progress
48% Bias Score
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
UK Insurer Vitality Offers Discounted Weight Loss Medication
Vitality, the UK's third-largest health insurer, is offering its 1.9 million members discounts of up to 20% on anti-obesity medications like Wegovy and Mounjaro, based on BMI and health conditions, to combat the £6.5 billion annual cost of obesity to the NHS.
Progress
40% Bias Score
Showing 37 to 48 of 128 results